Celltrion, Inc.
068270
Peringkat dalam Saham
#720
Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the... Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the development and manufacturing of protein-based therapies, including treatments for oncology. Its commercial portfolio features established products such as Remsima, Truxima, and Herzuma, alongside a range of generic pharmaceuticals and diagnostic kits for COVID-19. The company maintains an extensive pipeline of antibody biosimilars currently undergoing various stages of clinical evaluation. Late-stage (Phase 3) candidates include CT-P17, aimed at rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease (IBD); CT-P16, targeting metastatic colorectal and breast cancers; CT-P43, for inflammatory conditions like psoriasis, Crohn's disease, and ulcerative colitis; CT-P42, addressing diabetic macular edema; and CT-P59, developed for COVID-19. In Phase 2, CT-P27 is being tested for pandemic and seasonal influenza. Earlier in development, Phase 1 assets comprise CT-P39 for asthma and urticaria, CT-P41 for osteoporosis and bone loss, and CT-G20 for cardiomyopathy. Additionally, Celltrion maintains a collaboration with Inhalon Biopharma, Inc. to advance IN-006, an inhaled formulation of regdanvimab intended for the treatment of COVID-19 patients. Established in 2002, the company operates primarily from its headquarters in Incheon, South Korea.
Harga Saham
$146.63
Kapitalisasi Pasar
$33.44B
Perubahan (1 hari)
-1.52%
Perubahan (1 tahun)
23.60%
Negara
KR
Perdagangan Celltrion, Inc. (068270)
Kategori
Healthcare
Margin Operasi untuk Celltrion, Inc. (068270)
Margin Operasi per October 2026 TTM: 31.56%
Menurut laporan keuangan dan harga saham terbaru dari Celltrion, Inc., margin operasi saat ini (TTM) adalah 31.56%. Pada akhir 2024, margin operasi perusahaan adalah 13.83%.
Riwayat margin operasi untuk Celltrion, Inc. dari 2007 hingga 2026
Margin Operasi pada akhir setiap tahun
| Tahun | Margin Operasi | Mengubah |
|---|---|---|
| 2026 (TTM) | 31.56% | 12.43% |
| 2025 | 28.07% | 102.96% |
| 2024 | 13.83% | -53.79% |
| 2023 | 29.93% | 5.61% |
| 2022 | 28.34% | -27.89% |
| 2021 | 39.30% | 1.13% |
| 2020 | 38.86% | 14.94% |
| 2019 | 33.81% | 2.77% |
| 2018 | 32.90% | -37.50% |
| 2017 | 52.64% | 41.35% |
| 2016 | 37.24% | -13.21% |
| 2015 | 42.91% | 0.33% |
| 2014 | 42.77% | -3.10% |
| 2013 | 44.14% | -20.91% |
| 2012 | 55.81% | -13.15% |
| 2011 | 64.26% | 9.06% |
| 2010 | 58.92% | 19.51% |
| 2009 | 49.30% | 34.08% |
| 2008 | 36.77% | 1,237.09% |
| 2007 | 2.75% | 0.00% |
Margin Operasi untuk perusahaan sejenis atau pesaing
| Perusahaan | Margin Operasi | Perbedaan Margin Operasi | Negara |
|---|---|---|---|
| 38.59% | -98.78% |
US
|
|
| -149.01% | -104.72% |
US
|
|
| 25.57% | -99.19% |
AU
|
|
| 31.23% | -99.01% |
BE
|
|
| 28.81% | -99.09% |
NL
|
Apa itu Margin Operasi perusahaan?
Margin Operasi adalah indikator utama untuk menilai profitabilitas suatu perusahaan. Margin Operasi yang lebih tinggi umumnya lebih baik karena menunjukkan bahwa perusahaan mampu menjual produk atau layanan mereka dengan harga yang jauh lebih tinggi daripada biaya produksinya. Margin Operasi dihitung dengan membagi laba perusahaan dengan pendapatannya.